The 36-month beta value for LXRX is at 1.38. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for LXRX is 239.55M, and currently, shorts hold a 9.15% of that float. The average trading volume for LXRX on April 22, 2024 was 4.85M shares.
LXRX) stock’s latest price update
The stock price of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has jumped by 3.03 compared to previous close of 1.65. Despite this, the company has seen a fall of -9.09% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-16 that Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LXRX’s Market Performance
Lexicon Pharmaceuticals Inc (LXRX) has seen a -9.09% fall in stock performance for the week, with a -29.46% decline in the past month and a 23.19% surge in the past quarter. The volatility ratio for the week is 7.67%, and the volatility levels for the past 30 days are at 8.00% for LXRX. The simple moving average for the past 20 days is -15.52% for LXRX’s stock, with a -0.35% simple moving average for the past 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with Jefferies repeating the rating for LXRX by listing it as a “Hold.” The predicted price for LXRX in the upcoming period, according to Jefferies is $3 based on the research report published on March 07, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $10. The rating they have provided for LXRX stocks is “Overweight” according to the report published on August 12th, 2022.
JP Morgan gave a rating of “Neutral” to LXRX, setting the target price at $7 in the report published on January 29th of the previous year.
LXRX Trading at -27.50% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.13% of loss for the given period.
Volatility was left at 8.00%, however, over the last 30 days, the volatility rate increased by 7.67%, as shares sank -24.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.65% lower at present.
During the last 5 trading sessions, LXRX fell by -8.56%, which changed the moving average for the period of 200-days by -22.97% in comparison to the 20-day moving average, which settled at $1.9848. In addition, Lexicon Pharmaceuticals Inc saw 11.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who purchase 90,000 shares at the price of $1.05 back on Nov 16 ’23. After this action, COATS LONNEL now owns 914,359 shares of Lexicon Pharmaceuticals Inc, valued at $94,797 using the latest closing price.
COATS LONNEL, the Chief Executive Officer of Lexicon Pharmaceuticals Inc, purchase 10,000 shares at $1.01 during a trade that took place back on Nov 10 ’23, which means that COATS LONNEL is holding 824,359 shares at $10,100 based on the most recent closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -142.53 for the present operating margin
- 0.71 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -144.88. The total capital return value is set at -0.87. Equity return is now at value -167.06, with -82.89 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -1.61. The debt to equity ratio resting at 1.08. The interest coverage ratio of the stock is -13.11.
Currently, EBITDA for the company is -171.2 million with net debt to EBITDA at -0.5. When we switch over and look at the enterprise to sales, we see a ratio of 416.77. The receivables turnover for the company is 1.19for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.60.
Conclusion
In conclusion, Lexicon Pharmaceuticals Inc (LXRX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
